Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-02-05

Clinical Trial Update: Trial to Evaluate Efficacy of Pharmacogenetic Information Obtained With NEUROPHARMAGEN in Treatment of MDD Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pharmacogenetic information using NEUROPHARMAGEN in the treatment of major depressive disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NEUROPHARMAGEN

Snippet

Sponsor: AB Biotics, SA | Conditions: Depressive Disorder, Major | Phase 3 | Status: COMPLETED